By Sam Boughedda
Investing.com — ImmunoGen Inc (NASDAQ:) stock jumped at the open today after it announced positive results from its trial of mirvetuximab soravtansine in ovarian cancer.
Notably, the SORAYA trial met its primary endpoint with a confirmed objective response rate of 32.4%.
ImmunoGen shares are currently up over 37%.
The company said it aims to complete the Biologics License Application for mirvetuximab, its potential treatment for patients with platinum-resistant ovarian cancer, by submitting an application to the Food and Drug Administration for accelerated approval in the first quarter of 2022.
Mark Enyedy, ImmunoGen’s president and CEO, said it is an “exciting moment, both for the field of ovarian cancer and for ImmunoGen,” with the outcomes from the SORAYA trial “further validate our longstanding history of innovation in ADCs.”
“Commercial preparations are well underway to support the potential launch of mirvetuximab next year,” he added.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.